Exencial Wealth Advisors LLC Sells 3,070 Shares of GSK plc (NYSE:GSK)

Exencial Wealth Advisors LLC cut its position in shares of GSK plc (NYSE:GSK) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,868 shares of the pharmaceutical company’s stock after selling 3,070 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in GSK were worth $1,551,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Indiana Trust & Investment Management Co boosted its holdings in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust purchased a new stake in GSK during the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its holdings in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in GSK during the 4th quarter valued at about $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Up 0.9 %

NYSE GSK opened at $38.79 on Thursday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a 50 day simple moving average of $35.25 and a two-hundred day simple moving average of $37.20. The stock has a market cap of $80.38 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.05%. GSK’s payout ratio is currently 98.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on GSK shares. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.